



#13/IDS 1512
Patent 08
231/003 04
99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:)
THOMAS KIPPS et al.) Group Art Unit: 1644
Serial No.: 08/982,272) Examiner: P. Gambel
Filed: December 1, 1997)
For: NOVEL EXPRESSION VECTORS)
CONTAINING ACCESSORY MOLECULE)
LIGAND GENES AND THEIR USE FOR)
IMMUNOMODULATION AND)
TREATMENT OF MALIGNANCIES AND)
AUTOIMMUNE DISEASE)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Attached is a copy of a publication, listed on the accompanying Form PTO-1449, which has come to applicant's attention. In compliance with the Applicants' duty under 37 CFR 1.97-98, the following information is brought to the attention of the Examiner. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner.

07/21/1999 AIBRAHIM 00000035 08982272

02 FC:126

240.00 OP

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

July 13, 1999
Date of Deposit

Jeanette M. Olivera
Name of Person Mailing Paper

Jeanette M. Olivera
Signature of Person Mailing Paper

The items identified in this Information Disclosure Statement may or may not be "material" pursuant to 37 CFR 1.56 and the submission thereof by Applicants shall not be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR 1.97(h)), or even qualifies as "prior art" under 35 U.S.C. § 102 with respect to this invention unless specifically designated by Applicants as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR 1.56, exists.

The attached Supplemental Information Disclosure Statement is being filed in accordance with 37 CFR §§ 1.97(c) and 1.98. This IDS is being filed after an action on the merits but before a Final Action under § 1.113 or a Notice of Allowance under § 1.311. Enclosed is a check to cover the fee pursuant to 37 CFR § 1.17(p). In the event that this IDS is not received before a Final Action under § 1.113 or a Notice of Allowance under § 1.311, the Applicant respectfully requests the filing of these papers to be considered a petition requesting consideration of this IDS pursuant to 37 CFR § 1.97(d). The Examiner is hereby authorized to charge any additional fee(s) required by this paper to Lyon & Lyon's Deposit Account No. 12-2475.

Respectfully submitted,

LYON & LYON LLP

Dated: 7/13/91

By: Jeffrey W. Guise
Jeffrey W. Guise
Reg. No. 34,613

633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
(619) 552-8400
(213) 955-0440 (Fax)